US 9492433
Pharmaceutical composition for the treatment of Duchenne muscular dystrophy
granted A61KA61K31/423A61K47/10
Quick answer
US patent 9492433 (Pharmaceutical composition for the treatment of Duchenne muscular dystrophy) held by Summit Corporation Plc expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Summit Corporation Plc
- Grant date
- Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 47
- CPC classes
- A61K, A61K31/423, A61K47/10, A61K47/14, A61K47/26